ArticleProceedings of the National Academy of Sciences of the United States of America2019
Decreased humoral immunity to mumps in young adults immunized with MMR vaccine in childhood.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00962819 (Persistence of Humoral and Cellular Immune Responses Following Age-appropriate Vaccination With the MMR Vaccine), which is not on this map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Persistence of Humoral and Cellular Immune Responses Following Age-appropriate Vaccination With the MMR Vaccine
Who cites it
42 citing papers in PubMed.
- Mumps resurgence despite MMR: Limitations of current vaccines and the need for new strategies.Human vaccines & immunotherapeutics · 2026Review
- A Chimeric Virus Approach Reveals the Matrix (M) Gene as a Critical Modulator of Mumps Virus Neurovirulence.Vaccines · 2026Article
- High-dimensional profiling following third MMR vaccination or mumps virus infection reveals individuals with suboptimal immunity.Communications medicine · 2026Article
- Age- and Sex-Dependent Heterogeneity in Mumps Virus Immunity Among US Blood Donors Born Between 1928-1993.The Journal of infectious diseases · 2026Article
- Sex-based differences in mumps immunity after a third dose of measles-mumps-rubella vaccine.Vaccine · 2026Article
- Serological Mumps Evaluation of Medical Students in Catalonia (Spain): Is a Third Dose of Vaccine Needed?Journal of medical virology · 2026Article
- Decreasing Antibody Titers and the Slow Decay of Measles Immunity in Mexico's Current Epidemiological Landscape.Vaccines · 2026Article
- Mumps Virus: Replication, Immune Response, and the Changing Landscape of Vaccine Effectiveness.Pathogens (Basel, Switzerland) · 2026Review
- A cross-sectional study of seroprevalence in Armenia, 2025: measles, mumps, rubella, and diphtheria.Frontiers in public health · 2026Article
- Whole-genome analysis of mumps virus genotype F in Shandong, China (2006-2018).Frontiers in microbiology · 2026Article
- Antibody Levels Against Mumps Virus in Children After Implementation of the Two-Dose MMR Vaccine Policy - Fujian Province, China, 2023.China CDC weekly · 2025Article
- Age-Specific Seroprevalence of Measles, Mumps, and Rubella IgG across All Age Groups in Chonburi Province, Thailand after the Coronavirus Disease 2019 Pandemic.The American journal of tropical medicine and hygiene · 2025Article
- Serological status of measles, mumps, and rubella antibodies in HIV-positive women of childbearing age at a referral hospital in Iran.AIDS research and therapy · 2025Article
- Patterns of Decline in Measles, Mumps, and Rubella Neutralizing Antibodies and Protection Levels Through 10 Years After a Second and Third Dose of MMR Vaccine.Open forum infectious diseases · 2025Article
- Seronegative Vaccinees May Not Benefit From Multiple Booster Doses of MMR Vaccine in Restoring Immunity.Journal of medical virology · 2024Observational
- Structure-based design of glycoprotein subunit vaccines for mumps.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Article
- Serologic Cross-Reactivity between the Mumps Virus Vaccine Genotype A Strain and the Circulating Genotype G Strain.Viruses · 2024Article
- Serosurveillance for Measles and Rubella.Vaccines · 2024Review
- Identifying a Level of Neutralizing Antibody That Correlates With Protection From Clinical Mumps Disease During a 2017 Mumps Outbreak Among Military Service Members.Open forum infectious diseases · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
In the past decade, multiple mumps outbreaks have occurred in the United States, primarily in close-contact, high-density settings such as colleges, with a high attack rate among young adults, many of whom had the recommended 2 doses of mumps-measles-rubella (MMR) vaccine. Waning humoral immunity and the circulation of divergent wild-type mumps strains have been proposed as contributing factors to mumps resurgence. Blood samples from 71 healthy 18- to 23-year-old college students living in a non-outbreak area were assayed for antibodies and memory B cells (MBCs) to mumps, measles, and rubella. Seroprevalence rates of mumps, measles, and rubella determined by IgG enzyme-linked immunosorbent assay (ELISA) were 93, 93, and 100%, respectively. The index standard ratio indicated that the concentration of IgG was significantly lower for mumps than rubella. High IgG avidity to mumps Enders strain was detected in sera of 59/71 participants who had sufficient IgG levels. The frequency of circulating mumps-specific MBCs was 5 to 10 times lower than measles and rubella, and 10% of the participants had no detectable MBCs to mumps. Geometric mean neutralizing antibody titers (GMTs) by plaque reduction neutralization to the predominant circulating wild-type mumps strain (genotype G) were 6-fold lower than the GMTs against the Jeryl Lynn vaccine strain (genotype A). The majority of the participants (80%) received their second MMR vaccine ≥10 years prior to study participation. Additional efforts are needed to fully characterize B and T cell immune responses to mumps vaccine and to develop strategies to improve the quality and durability of vaccine-induced immunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.